Alpha-GPC
A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.
Evidence reviewed:
Mechanism of action
Alpha-GPC (alpha-glycerylphosphorylcholine) is the most bioavailable choline precursor. It delivers choline directly across the blood-brain barrier, where it is used to synthesise acetylcholine. It also supports cell membrane phospholipid synthesis. It is often marketed for growth hormone release, but a 2024 RCT at 630mg found no growth hormone difference versus placebo.
Clinical evidence summary
A multicenter RCT in mild-to-moderate Alzheimer's dementia (De Jesus Moreno, 2003, n=261) found 1200mg/day improved ADAS-Cog, MMSE and global scores versus placebo at 90 and 180 days, and a 2023 meta-analysis supports benefit in cerebrovascular cognitive impairment. In healthy men, a single 315–630mg dose improved Stroop performance but not N-Back or Flanker (Kerksick 2024). Sports trials are inconsistent: a lower-body force gain after 6 days at 600mg (Bellar 2015), no strength effect at 250–500mg for 7 days, and no power-output effect after a single 630mg dose.
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Acetylcholine Synthesis | strong | Large | 2 |
| Memory & Cognition | moderate | Moderate | 2 |
| Athletic Power Output | mixed | Small | 3 |
| Neuroprotection | moderate | Moderate | 2 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Cognition in Alzheimer's and cerebrovascular dementia (1200mg/day)
- Acute Stroop (executive) performance in healthy men
- Raises plasma choline
Side effects & cautions
- Well tolerated
- Headache if combined with other cholinergics
- 500mg/day significantly suppressed serum TSH (thyroid-stimulating hormone) in a 7-day trial
How to take
Stacking recommendations
Ingredients that pair well with Alpha-GPC and why.
Alpha-GPC provides immediate acetylcholine support; Lion's Mane drives long-term NGF synthesis. Neither overlaps mechanistically — a clean acute + long-term pairing.
Alpha-GPC handles acute memory encoding via acetylcholine; Bacopa handles memory consolidation and storage. Together they cover both encoding and consolidation stages of memory formation.
Huperzine A prevents acetylcholine breakdown while Alpha-GPC increases acetylcholine synthesis. Powerful combination in theory — but use with caution and low doses, as cholinergic overload (nausea, headache, muscle cramps) is a real risk. Not recommended without experience.
Frequently asked questions
Alpha-GPC vs Citicoline — which is better for focus?
Both are excellent. Alpha-GPC has a slight edge for acute cholinergic effects and is preferred for workout performance. Citicoline also provides cytidine (uridine precursor), giving it a broader neuroprotective profile. For pure focus and acetylcholine, Alpha-GPC wins slightly; for comprehensive brain health support, Citicoline is more complete. Don't stack them together — you'll get too much choline activity.
Is it safe to combine Alpha-GPC with Huperzine A?
Use caution. Both increase acetylcholine (Alpha-GPC via synthesis, Huperzine A via inhibiting breakdown). The combination is potent and can cause cholinergic overstimulation — symptoms include nausea, headache, excessive salivation, and muscle cramps. If combining, use lower doses of each (e.g. 200mg Alpha-GPC + 50mcg Huperzine A) and do not take daily.
Why does Alpha-GPC powder go sticky?
Alpha-GPC is highly hygroscopic — it absorbs water from the air quickly. This is normal and doesn't affect potency. Store in an airtight container in a cool, dry place. Capsule form avoids this problem entirely.
Is there a cardiovascular risk with Alpha-GPC?
Unresolved. The CARDIA cohort study (published 2024) linked higher plasma choline — not alpha-GPC supplements — with incident cardiovascular disease, while a meta-analysis of dietary choline intake found no association. No study has tested alpha-GPC supplementation directly for cardiovascular outcomes. If you have cardiovascular disease, discuss it with your doctor.
Alpha-GPC in Japan
Alpha-GPC — chemically L-alpha-glycerylphosphorylcholine, sn-glycero(3)phosphocholine — is entered under its chemical name in MHLW's 別添２「医薬品的効能効果を標ぼうしない限り医薬品と判断しない成分本質（原材料）リスト」, the half of Japan's food-drug demarcation list covering ingredients not automatically treated as pharmaceuticals when no drug-like claim is made. The consolidated list text records the entry as "sn―グリセロ(3)ホスホコリン" with the alternate name "L―α―グリセリルホスホリルコリン／sn―Glycero(3) phosphocholine", with no cross-reference marking it as also appearing on the exclusively-pharmaceutical list.
Where alpha-GPC sits on MHLW's list
MHLW's 食薬区分 lists work as a pair: 別添１ names ingredients treated exclusively as drugs, and 別添２ names ingredients not automatically drug-classified provided no drug-like efficacy is claimed for them. Alpha-GPC's chemical entry, "sn―グリセロ(3)ホスホコリン" (alternate name "L―α―グリセリルホスホリルコリン／sn―Glycero(3) phosphocholine"), sits in 別添２ in both the 令和2年3月31日 base text and the 令和5年2月17日 amendment. That placement is what allows glycerophosphocholine-based ingredients to be marketed as food in Japan without being treated as an unapproved drug, so long as the product carries no medicinal efficacy claim.
Products in Japan
None of the stacks we have audited are listed in our catalogue in Japan yet.
Consumer Affairs Agency (FFC)
Is alpha-GPC treated as a drug ingredient in Japan?
No — MHLW's consolidated food-drug list places alpha-GPC's chemical entry ("sn―グリセロ(3)ホスホコリン", alternate name "L―α―グリセリルホスホリルコリン／sn―Glycero(3) phosphocholine") on 別添２, the list of ingredients not automatically judged pharmaceutical when no drug-like claim is made, not on the exclusively-pharmaceutical list, and that placement holds in both consolidated revisions cited below.
Does the 別添２ listing mean a label may claim a cognitive effect?
No. 別添２ placement means the ingredient is not judged a pharmaceutical as long as no drug-like efficacy is claimed for it. A cognitive claim on a label would need its own basis — in Japan, a Foods with Function Claims notification to the Consumer Affairs Agency — independent of the ingredient's food-drug classification.
Sources: MHLW — 食薬区分における成分本質（原材料）の取扱いの例示の一部改正について (令和5年2月17日薬生監麻発第217001号), 別添２ entry · MHLW — 食薬区分における成分本質（原材料）の取扱いの例示 (令和2年3月31日薬生監麻発0331第9号), base list confirming 別添２ placement · MHLW — 別添2 heading: 医薬品的効能効果を標ぼうしない限り医薬品と判断しない成分本質（原材料）リスト, 1. 植物由来物等
Regulatory note
本ページは教育目的の編集コンテンツであり、医学的助言を構成するものではありません。日本国内で販売される機能性表示食品（FFC）および特定保健用食品（FOSHU）は、消費者庁への届出または許可を必要とします。届出のない輸入品については、日本の薬機法（旧薬事法）の下で疾病治療を示唆する表現は規制されます。サプリメントを開始する前に、必ず資格のある医療専門家にご相談ください。This page is editorial and not medical advice. Foods with Function Claims (FFC) and Foods for Specified Health Uses (FOSHU) sold in Japan require notification or approval from the Consumer Affairs Agency. Imported products without notification cannot make disease-treatment claims under the Pharmaceuticals and Medical Devices (PMD) Act. Consult a qualified healthcare professional before starting any supplement.
Sources (7)expand
- PMID 36683513Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis (2023)
- PMID 12637119Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate (De Jesus Moreno, 2003) (2003)
- PMID 39683633Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men (2024)
- PMID 26582972The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength (Bellar et al., 2015) (2015)
- PMID 29042830Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance (2017)
- PMID 1428296A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers (1992)
- PMID 37865185Choline metabolites and incident cardiovascular disease in a prospective cohort of adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. (2024)